Evidence map›Paper›PMID 30045927›Full record

ArticleMolecular cancer therapeutics2018

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439.

Yongkang Zou, Zhi Qi, Weilong Guo, Liuzhen Zhang, Marcus Ruscetti, Tanu Shenoy, Ningshu Liu, Hong Wu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Yongkang Zou *The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences and Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, China.
Zhi Qi *The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences and Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, China.
Weilong GuoThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences and Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, China.
Liuzhen ZhangThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences and Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, China.
Marcus RuscettiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4394-2087
Tanu ShenoyDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California.
Ningshu LiuBayer AG, Drug Discovery TRG Oncology, Berlin, Germany.
Hong WuThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking-Tsinghua Center for Life Sciences and Beijing Advanced Innovation Center for Genomics, Peking University, Beijing, China. hongwu@pku.edu.cn.
Center for Life Sciences · CNUniversity of California, Los Angeles · USDrug Discovery Laboratory (Norway) · NO

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Influences of the Microenvironment on Cancer Stem CellsU01CA164188 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NELSON, PETER S, WITTE, OWEN N. · 2011 to 2015
$2.9M
NCI NIH HHS P50 CA092131NCI NIH HHS T32 CA009056NCI NIH HHS U01 CA164188
6 · The paper itself

Abstract

Targeting the PI3K pathway is a promising strategy for treating prostate cancers with PTEN-loss. However, current anti-PI3K therapies fail to show long lasting

Indexed as

AnimalsB-LymphocytesCell Line, TumorCell ProliferationClass Ia Phosphatidylinositol 3-KinaseDisease ProgressionHumansImmunohistochemistryImmunophenotypingLymphocytes, Tumor-InfiltratingMaleMiceProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantProtein Kinase InhibitorsPTEN PhosphohydrolaseClass Ia Phosphatidylinositol 3-KinaseProtein Kinase InhibitorsPTEN Phosphohydrolase

Identifiers

PMID30045927
PMCPMC6168338
OpenAlexW2883744836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.